The Role of Hepatitis C Virus in Parkinson’s Disease

Abstract

Background: Parkinson's disease (PD) is the most common neurodegenerative disorder after Alzheimers disease. As known, the risk of developing PD is multifactorial, and (HCV) infection is one of the risk factors. Case report: Patient 54 years old male. Diagnosis: HCV+ethanol liver cirrhosis, decompensated. Child stage B-C. Complications: portal hypertension, ascites, splenomegaly, hepatic encephalopathy I-II with hands tremor and hiccups. Investigations: HCV PCR- positive, G1b, PLT-101 × 103/lL, bilirubin total-38.5 μmol/L, bilirubin direct-24.7 μmol/L, AsAT- 47.4 U/L, ALAT-31.7 U/L, albumin-33.62 g/l, GGT-63.91 U/L, Pt time-20.90 s, INR-2.07 f, AFP-2.80 ng/mL, glucose- 15.89 mmol/L. Due to receiving pathogenetic and symptomatic treatment disease undergone to compensated state, followed by anti-virial treatment in 2017, for 3 months (DAA with SVR). Following up of patient showed aviremia with the normal level of serum amiak, but hands tremor and hiccups are still remain. After the neurogist's consultation he was diagnosed Parkonsin's disease with asymmetrical start. He is getting treatment for Parkinson's disease with improvement of neurological symptoms and compensated liver cirrhosis. Conclusions: HCV infection is a systemic disease with the hepatic and extrahepatic manifestations, including central nervous system. HCV-positive patients need regular neurological evaluation to allow for early detection of PD. Optimal treatment of HCV infection should take into account extrahepatic, including brain, manifestations of HCV infection.